Cure Today10h
Cabometyx Combo Maintains Progression-Free Survival Benefit in Advanced RCC
Final results were consistent with previously conducted research in patients with advanced renal cell carcinoma treated with ...
The American Journal of Managed Care6h
Can a New Therapeutic Combo Address a Rare Form of RCC?
Investigators from Shanghai, China, report responses above 90% by using levantinib and tislelizumab to treat patients with a ...
oncnursingnews10h
Cabozantinib Combo Maintains PFS for Advanced RCC at Follow-Up
New results uphold previous findings regarding the efficacy of cabozantinib, nivolumab, and ipilumumab arm for advanced renal ...
UroToday5h
ASCO GU 2025: Racial Disparities in Renal Cell Carcinoma Histology and Outcomes: Insights from the French Kidney Cancer Research Network (UroCCR-191)
American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA was host to the ...
UroToday11h
ASCO GU 2025: Real-World Treatment Patterns and Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma (mRCC) in the US Community Setting.
American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA between February 13 th and 15 th 2025, was host to the Poster Session C: Renal Cell Cancer; ...